Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698257 | 0.78 | CA12 (0.52) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL698258 | 0.78 | CA12 (0.52) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL364908 | 0.77 | — | — | |
| SCHEMBL2520895 | 0.76 | CA12 (0.50) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3870049 | 0.76 | CA12 (0.50) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3422335 | 0.76 | CA12 (0.50) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL1267862 | 0.76 | CA12 (0.61) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL5199864 | 0.76 | CA12 (0.50) | EPHX2CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL5112582 | 0.76 | CA12 (0.50) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3077421 | 0.76 | CA12 (0.50) | EPHX2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20240140945-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-05-02 | — | — | US | disclosed |
| EP-4326719-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-109593096-B | Tricyclic heterocycles as BET protein inhibitors | 因赛特公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-5043337-A | Insecticidal pyrimidin-4-yl carbamates | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
| US-4546102-A | CARDIOTONIC AGENTS | BOEHRINGER INGELHEIM KG (DE) | 1985-10-08 | — | — | US | disclosed |
| US-4505735-A | CONTAIN CYANOMETHYL GROUP AND ESTERIFIED METHYLENE PHOSPHONIC ACID | MONSANTO CO. (US) | 1985-03-19 | — | — | US | disclosed |
| US-4256881-A | Blocked benzotriazole compounds as development restrainer precursors | EASTMAN KODAK COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
| US-4255510-A | DIFFUSION TRANSFER, AZOLES | EASTMAN KODAK COMPANY (US) | 1981-03-10 | — | — | US | disclosed |
| US-4252943-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4217359-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4101571-A | REACTING SULFAMIC ACIDS WITH PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 1978-07-18 | — | — | US | disclosed |
| US-3941783-A | Process for the production of N,N-disubstituted carboxylic amides | ESZAKMAGYARORSZAGI VEGYIMUVEK (HU) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140945-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | EPHX2 2214/4885CA12 4806/4885CA1 4840/4885 |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | EPHX2 3568/4885CA12 4823/4885CA1 4768/4885 |
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | EPHX2 1830/4885CA12 2419/4885CA1 2811/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | EPHX2 3568/4885CA12 4823/4885CA1 4768/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | EPHX2 2214/4885CA12 4810/4885CA1 4841/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | EPHX2 3568/4885CA12 4823/4885CA1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.